3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
6
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Skin Diseases
1
Salivary Gland Neoplasms
1
Ovarian Neoplasms
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Advanced Prostate Cancer
1
Interventions
binimetinib
2
Watchful Waiting
2
Aminolevulinic Acid
2
palbociclib
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Paclitaxel
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Dacarbazine
1
Cantharidin
1
BF-200 ALA
1
Anastrozole
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Diseases
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled